Most Read Articles
Popular Stories
RADAR on Medicare Advantage
-
From engaging with patients and scheduling appointments to assisting with chart reviews and predicting fall risk, artificial intelligence can serve a wide range of purposes in Medicare Advantage and will play an...
-
“AI can be used for good or for evil,” stated CMS administrator nominee Mehmet Oz, M.D., during his recent Senate confirmation hearing. Appearing before the Senate Finance Committee on March 14, Oz repeatedly...
HEALTH PLAN WEEKLY
-
Since Donald Trump returned to the presidency, officials in several states have moved to resurrect their Medicaid work requirements demonstrations. During the confirmation hearing of Mehmet Oz, M.D., Trump’s...
-
As the federal government considers potential drastic cuts to Medicaid funding, vulnerable children could be impacted because Medicaid covers nearly all children in foster care, according to speakers who discussed the...
Radar On Speciality Pharmacy
-
The cell and gene therapy (CGT) space seems to be a bit of a mixed bag recently. While last year’s accomplishments included FDA approvals of two new first-in-class treatments for solid tumors and the first...
-
As CMS undergoes its pricing negotiations on the second round of drugs under the Medicare Drug Price Negotiation Program, a recent report reveals that manufacturer concerns over the program’s potential threat...
RADAR ON DRUG BENEFITS
-
Extending inflation-based prescription drug rebates to all commercial health plans, rather than just applying them to the Medicare program, could potentially save as much as $8.1 billion annually,...
-
A recent Institute for Clinical and Economic Review (ICER) report found that Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Breo Ellipta (fluticasone/vilanterol), two chronic obstructive...
About AIS Health
AIS Health is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. AIS Health maintains journalistic independence from our parent company, MMIT. We are committed to integrity in reporting and bringing transparency to health industry data.
The Latest
Complimentary Publications
Premium Categories
Premium Categories
Get an actionable understanding of the business of health care and pharmaceuticals
Sign up for publications to get unmatched business intelligence delivered to your inbox.